Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market
Details :
Product Name : Pink Kush
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 27, 2023
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study
Details :
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study
Details :
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : $16.0 million
Deal Type : Funding
MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC
Details :
Product Name : T2:C100
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 08, 2022
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : $16.0 million
Deal Type : Funding
Lead Product(s) : Cannabinoid,Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details :
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Cannabinoid,Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabigerol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details :
Product Name : CBG/CBD
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Cannabigerol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : CBD50
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : McMaster University
Deal Size : Undisclosed
Deal Type : Agreement
Details :
Product Name : T2:C100
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 21, 2021
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : McMaster University
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : European Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details :
Product Name : Pink Kush
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 04, 2021
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : European Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement